Showing results (81-90 of 117) with videos related to
Sort By:
Pageof 12
The Journal of Urology|November 16, 2020
T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at DiagnosisFlorus C de Jong, Robert F Hoedemaeker, Vebjørn Kvikstad, et al.European Urology Oncology|May 19, 2019
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative ReviewYair Lotan, Peter C Black, Laura Caba, et al.The Journal of Urology|November 22, 2011
The FGFR3 mutation is related to favorable pT1 bladder cancerBas W G van Rhijn, Theo H van der Kwast, Liyang Liu, et al.Verhandlungen Der Deutschen Gesellschaft Fur Pathologie|September 18, 2007
[Urothelial neoplasms in individuals younger than 20 years show very few genetic alterations and have a favourable clinical outcome]Johannes Giedl, Peter J Wild, Robert Stoehr, et al.European Urology|March 13, 2013
Outcomes of a bladder cancer screening program using home hematuria testing and molecular markersChris H Bangma, Stacy Loeb, Martijn Busstra, et al.Virchows Archiv : an International Journal of Pathology|April 15, 2014
Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp geneticsTilman T Rau, Abbas Agaimy, Anastasia Gehoff, et al.World Journal of Urology|January 3, 2025
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCGFlorus C de Jong, Vebjørn Kvikstad, Robert F Hoedemaeker, et al.Journal of Medical Genetics|April 14, 2012
Keratinocytic epidermal nevi are associated with mosaic RAS mutationsChristian Hafner, Agusti Toll, Susanne Gantner, et al.The Journal of Urology|January 4, 2017
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter StudyWillemien Beukers, Kirstin A van der Keur, Raju Kandimalla, et al.European Urology|January 2, 2008
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective studyMaximilian Burger, Madelon N M van der Aa, Johanna M M van Oers, et al.Pageof 12